The following table details the insider trading activities
(stock purchases, stock sales, and stock option exercises) of Hagen Brett R since 2021.
This trader's CIK number is 1681782.
At the time of last reporting, Hagen Brett R was the Chief Accounting Officer of Kalaris Therapeutics, Inc.. (stock ticker symbol KLRS).
Also see all insider trading activities at Kalaris Therapeutics, Inc..
| Insider Buying | Insider Sales | Option Exercises | |||||
|---|---|---|---|---|---|---|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
| 2025 | KLRS | 0 | $0 | 1,335 | $9,247 | 0 | $0 |
| 2024 | KLRS | 0 | $0 | 55,003 | $39,516 | 0 | $0 |
| 2023 | KLRS | 0 | $0 | 11,314 | $49,349 | 0 | $0 |
| 2022 | KLRS | 0 | $0 | 15,518 | $130,817 | 0 | $0 |
| 2021 | KLRS | 0 | $0 | 6,911 | $286,447 | 0 | $0 |
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2025-03-26 | KLRS | Sale | 907 | 8.97 | 8,134 |
| 2025-02-21 | ALVR | Sale | 96 | 10.08 | 967 |
| 2025-01-10 | ALVR | Sale | 332 | .44 | 146 |
| 2024-11-19 | ALVR | Sale | 554 | .55 | 304 |
| 2024-11-05 | ALVR | Sale | 1,655 | .86 | 1,431 |
| 2024-10-22 | ALVR | Sale | 486 | .77 | 373 |
| 2024-10-21 | ALVR | Sale | 479 | .78 | 373 |
| 2024-10-03 | ALVR | Sale | 301 | .81 | 245 |
| 2024-08-05 | ALVR | Sale | 1,692 | .73 | 1,243 |
| 2024-07-02 | ALVR | Sale | 304 | .72 | 218 |
| 2024-05-03 | ALVR | Sale | 1,597 | .80 | 1,271 |
| 2024-04-19 | ALVR | Sale | 473 | .75 | 355 |
| 2024-04-22 | ALVR | Sale | 480 | .75 | 360 |
| 2024-02-20 | ALVR | Sale | 494 | .69 | 343 |
| 2024-02-08 | ALVR | Sale | 11,150 | .67 | 7,492 |
| 2024-02-05 | ALVR | Sale | 5,792 | .67 | 3,880 |
| 2024-01-23 | ALVR | Sale | 901 | .67 | 604 |
| 2024-01-04 | ALVR | Sale | 310 | .64 | 198 |
| 2023-12-27 | ALVR | Sale | 28,335 | .73 | 20,826 |
| 2023-11-17 | ALVR | Sale | 403 | 1.63 | 657 |
| 2023-10-19 | ALVR | Sale | 358 | 1.58 | 565 |
| 2023-10-20 | ALVR | Sale | 357 | 1.54 | 550 |
| 2023-10-03 | ALVR | Sale | 222 | 1.98 | 438 |
| 2023-08-17 | ALVR | Sale | 1,653 | 2.50 | 4,125 |
| 2023-07-20 | ALVR | Sale | 342 | 3.35 | 1,144 |
| 2023-07-19 | ALVR | Sale | 342 | 3.56 | 1,218 |
| 2023-06-09 | ALVR | Sale | 5,045 | 5.64 | 28,453 |
| 2023-04-19 | ALVR | Sale | 348 | 3.71 | 1,290 |
| 2023-04-20 | ALVR | Sale | 349 | 3.63 | 1,265 |
| 2023-01-20 | ALVR | Sale | 338 | 5.14 | 1,738 |
| 2023-01-19 | ALVR | Sale | 1,557 | 5.08 | 7,906 |
| 2022-10-19 | ALVR | Sale | 345 | 9.36 | 3,229 |
| 2022-10-21 | ALVR | Sale | 11,334 | 8.45 | 95,794 |
| 2022-10-24 | ALVR | Sale | 2,000 | 8.13 | 16,270 |
| 2022-04-20 | ALVR | Sale | 276 | 6.68 | 1,844 |
| 2022-01-20 | ALVR | Sale | 1,563 | 8.75 | 13,680 |
| 2021-02-22 | ALVR | Sale | 800 | 43.14 | 34,508 |
| 2021-02-18 | ALVR | Sale | 741 | 39.87 | 29,546 |
| 2021-02-16 | ALVR | Sale | 3,050 | 42.25 | 128,856 |
| 2021-02-17 | ALVR | Sale | 2,320 | 40.32 | 93,537 |
Insider trading activities including stock purchases, stock sales, and option exercises listed in the above table cannot be completely guaranteed as to their accuracy. For more information regarding the trades made by Hagen Brett R (Chief Accounting Officer of Kalaris Therapeutics, Inc. at the time of this reporting) see the Securities and Exchange Commission (SEC) website.